We are using cookies to give you the best experience on our site. Cookies are files stored in your browser and are used by most websites to help personalise your web experience. By continuing to use our website without changing the settings, you are agreeing to our use of cookies.

Share
  • Facebook
  • Twitter
  • Linked In
  • Google+
back top
Regentis Biomaterials Receives European CE Mark Approval for GelrinC

1300 members from 70 countries Join ICRS

Regentis Biomaterials Receives European CE Mark Approval for GelrinC

OR AKIVA, Israel and PRINCETON, New Jersey, August 28, 2017 /PRNewswire/ — Regentis Biomaterials Ltd., a privately held company developing proprietary hydrogels for tissue regeneration, announced today it has received European CE mark approval for its GelrinC® biodegradable implant.

The approval covers GelrinC manufactured using denatured human fibrinogen and expands upon the existing CE mark for a version containing denatured bovine-sourced fibrinogen. This latest approval enables Regentis to begin accessing new global markets, and helping more patients suffering from damaged articular knee cartilage. “Since a CE mark is recognized internationally, this key approval opens the door to making the product available in many other territories,” said Regentis Biomaterial CEO Alastair Clemow, Ph.D.

Read More:

OR AKIVA, Israel and…
ICRShttps://cartilage.org/content/uploads/icrs.jpg
Regentis Biomaterials Receives European CE Mark Approval for GelrinC